Endogenous and Therapeutic 25-Hydroxycholesterols May Worsen Early SARS-CoV-2 Pathogenesis in Mice

• Published in: American journal of respiratory cell and molecular biology Vol. 69; no. 6; pp. 638 - 648
• Main Authors: Fessler, Michael B, Madenspacher, Jennifer H, Baker, Paul J, Hilligan, Kerry L, Bohrer, Andrea C, Castro, Ehydel, Meacham, Julie, Chen, Shih-Heng, Johnson, Reed F, McDonald, Jeffrey G, Martin, Negin P, Tucker, Charles J, Mahapatra, Debabrata, Cesta, Mark, Mayer-Barber, Katrin D
• Format: Journal Article
• Language: English
• Published: United States American Thoracic Society 01.12.2023
• Subjects: ACE2; Angiotensin; Angiotensin-converting enzyme 2; Animal models; Animals; Antiviral Agents - pharmacology; Antiviral drugs; Cholesterol; Coronaviruses; COVID-19; Cytokines; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Hydroxycholesterols - pharmacology; Mice; Pathogenesis; Peptidyl-dipeptidase A; Pneumonia; Receptors, G-Protein-Coupled; Rodents; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Side effects; Weight Loss; cholesterol-25-hydroxylase; 25-hydroxycholesterol; SARS-CoV-2; pneumonia; EBI2
• DOI: 10.1165/rcmb.2023-0007OC
• ISSN: 1044-1549

Oxysterols (i.e., oxidized cholesterol species) have complex roles in biology. 25-Hydroxycholesterol (25HC), a product of the activity of cholesterol-25-hydroxylase (CH25H) on cholesterol, has recently been shown to be broadly antiviral, suggesting therapeutic potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, 25HC can also amplify inflammation and be converted by CYP7B1 (cytochrome P450 family 7 subfamily B member 1) to 7α,25-dihydroxycholesterol, a lipid with chemoattractant activity, via the G protein-coupled receptor EBI2 (Epstein-Barr virus-induced gene 2)/GPR183 (G protein-coupled receptor 183). Here, using studies and two different murine models of SARS-CoV-2 infection, we investigate the effects of these two oxysterols on SARS-CoV-2 pneumonia. We show that although 25HC and enantiomeric-25HC are antiviral against human endemic coronavirus-229E, they did not inhibit SARS-CoV-2; nor did supplemental 25HC reduce pulmonary SARS-CoV-2 titers in the K18-human ACE2 (angiotensin-converting enzyme 2) mouse model . Treatment with 25HC also did not alter immune cell influx into the airway, airspace cytokines, lung pathology, weight loss, symptoms, or survival but was associated with increased airspace albumin, an indicator of microvascular injury, and increased plasma proinflammatory cytokines. Conversely, mice treated with the EBI2/GPR183 inhibitor NIBR189 displayed a modest increase in lung viral load only at late time points but no change in weight loss. Consistent with these findings, although and 25HC were upregulated in the lungs of SARS-CoV-2-infected wild-type mice, lung viral titers and weight loss in and mice infected with the β variant were similar to those in control animals. Taken together, endogenous 25HCs do not significantly regulate early SARS-CoV-2 replication or pathogenesis, and supplemental 25HC may have proinjury rather than therapeutic effects in SARS-CoV-2 pneumonia.